KALARIS THERAPEUTICS INC (KLRS) Stock Earnings & Estimates
USA - NASDAQ:KLRS - US4829291065 - Common Stock
6.3706 USD
-0.53 (-7.67%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.14M | 170K -85.09% | -100.00% | 390.15K | 27.2M | -100.00% | 6.8M | 28.594M 320.50% | 95.708M 234.71% | 233.43M 143.90% | ||||||
| EBITDA YoY % growth | -3.6M | -26.68M -641.11% | -73.44M -167.02% | -166.26M -138.11% | -176.978M -0.50% | -192.667M -5.94% | -70.115M 61.18% | -55.995M 20.14% | -62.525M -11.66% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -3.6M | -26.7M -641.67% | -75.066M -167.08% | -169.409M -138.14% | -184.517M -0.81% | -189.785M -5.72% | -65.032M 69.61% | -48.729M 11.40% | -60.276M -23.70% | -43.531M 27.78% | -84.864M -94.95% | -102.306M -20.55% | -124.032M -21.24% | -192.576M -55.26% | -172.992M 10.17% | |
| Operating Margin | -315.79% | -15,705.88% | N/A | -43,421.52% | N/A | N/A | N/A | N/A | N/A | -160.04% | N/A | -1,504.50% | -433.77% | -201.21% | -74.11% | |
| EPS YoY % growth | N/A | N/A | -105.96 | -61.86 40.53% | -52.71 17.88% | -40.96 25.78% | -0.51 98.68% | -3.72 -634.89% | -2.54 31.64% | -1.07 57.78% | -1.43 -33.39% | -1.14 20.64% | -0.72 36.32% | -0.83 -14.08% | -0.59 28.40% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.67 -796.50% | -0.65 74.10% | -0.67 -9.32% | -0.58 9.63% | -0.72 -8.00% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -13.529M 30.70% | -14.017M -35.38% | -14.563M -18.82% | -15.178M -17.46% | -14.076M -4.04% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | -0.64 -560.47% | -0.67 | 0.03 | 3.88% |
| Q2 2025 Q2Q % growth | -0.61 46.96% | -0.53 | -0.08 | -15.01% |
| Q1 2025 Q2Q % growth | -2.52 57.86% | -0.79 | -1.73 | -218.79% |
| Q4 2024 Q2Q % growth | 99.10% | -0.07 | % | |
| Q3 2024 Q2Q % growth | 98.92% | -0.10 | % | |
| Q2 2024 Q2Q % growth | -1.15 89.58% | -2.46 | 1.31 | 53.31% |
| Q1 2024 Q2Q % growth | -5.98 40.91% | -3.68 | -2.30 | -62.70% |
| Q4 2023 Q2Q % growth | -8.28 2.70% | -10.04 | 1.76 | 17.54% |
| Q3 2023 Q2Q % growth | -8.97 22.00% | -9.76 | 0.79 | 8.09% |
| Q2 2023 Q2Q % growth | -11.04 30.43% | -10.56 | -0.48 | -4.58% |
| Q1 2023 Q2Q % growth | -10.12 36.23% | -10.91 | 0.79 | 7.23% |
| Q4 2022 Q2Q % growth | -8.51 59.78% | -12.75 | 4.24 | 33.24% |
| Q3 2022 Q2Q % growth | -11.50 30.56% | -12.36 | 0.86 | 6.93% |
| Q2 2022 Q2Q % growth | -15.87 -15.00% | -17.13 | 1.26 | 7.33% |
| Q1 2022 Q2Q % growth | -15.87 -38.00% | -18.69 | 2.82 | 15.09% |
| Q4 2021 Q2Q % growth | -21.16 -170.59% | -19.08 | -2.08 | -10.90% |
| Q3 2021 Q2Q % growth | -16.56 -24.14% | -12.90 | -3.66 | -28.34% |
| Q2 2021 Q2Q % growth | -13.80 | -11.50 | -2.30 | -20.05% |
| Q1 2021 Q2Q % growth | -11.50 | -9.44 | -2.06 | -21.79% |
| Q4 2020 Q2Q % growth | -7.82 | -9.85 | 2.03 | 20.63% |
| Q3 2020 Q2Q % growth | -13.34 | -7.04 | -6.30 | -89.54% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2020 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0.34% | -20.15% | 0% | -16.61% |
| Revenue | N/A | N/A | N/A | N/A |